文献速递糖尿病肥胖与代谢综合征

早发2型糖尿病与替尔泊肽治疗:SURPASS临床试验项目的事后分析

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
PubMed 文献 · Diabetes Care · 2024-01-01

该事后分析比较SURPASS项目中3792例早发与晚发2型糖尿病参与者的基线特征及替尔泊肽治疗第40周或第52周时血糖、体重、腰围、血脂和血压的变化。早发者虽更年轻但血糖更高、代谢状况更差;替尔泊肽治疗下两组改善程度相似。

要点

  • 早发2型糖尿病者虽更年轻,但基线血糖水平和整体代谢健康状况更差。
  • 替尔泊肽治疗下,早发与晚发2型糖尿病者的HbA1c、体重和心血管代谢指标改善程度相似。
  • 替尔泊肽在早发2型糖尿病中的长期结局尚需未来研究确定。

核心结论

  • 尽管早发2型糖尿病参与者更年轻,但其基线血糖水平更高、整体代谢健康状况更差。
  • 在此事后分析中,无论2型糖尿病诊断年龄如何,替尔泊肽治疗下HbA1c、体重和心血管代谢指标的改善程度相似。
  • 尚需未来研究确定替尔泊肽在早发2型糖尿病中的长期结局。

研究设计与样本

  • SURPASS临床试验项目的事后分析,共纳入3792例早发与晚发2型糖尿病参与者。
  • 比较基线特征及第40周(SURPASS-1和SURPASS-2)或第52周(SURPASS-3)时平均HbA1c、体重、腰围、血脂和血压的变化。
  • 分析按研究进行,使用参与者仍在指定治疗且未因持续高血糖使用补救药物时的数据。

主要发现

  • SURPASS-2基线时,早发与晚发2型糖尿病参与者相比:更年轻,糖尿病病程更长(9年 vs 7年,P < 0.001),血糖水平更高(8.5% vs 8.2%,P < 0.001),体重更高(97 kg vs 93 kg,P < 0.001),BMI更高(35 kg/m2 vs 34 kg/m2,P < 0.001),血脂谱异常程度相似(如甘油三酯167 mg/dL vs 156 mg/dL)。
  • 第40周时,替尔泊肽治疗下两组均观察到相似的HbA1c改善(-2.6% vs -2.4%)、体重改善(-14 kg vs -13 kg)、腰围改善(-10 cm vs -10 cm)、甘油三酯改善(-26% vs -24%)、HDL改善(7% vs 7%)和收缩压改善(-6 mmHg vs -7 mmHg)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS: This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS: At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P < 0.001) higher glycemic levels (8.5% vs. 8.2%, P < 0.001), higher BW (97 vs. 93 kg, P < 0.001) and BMI (35 vs. 34 kg/m2, P < 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS: Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Zeitler P, Galindo RJ, Davies MJ, et al. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 2024. PMID: 38639997. doi:10.2337/dc23-2356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。